|
Clinical factor
|
Entire cohort [cases (%)]
|
CNS relapse cohort [cases (%)]
|
|---|
|
CHOP
|
R-CHOP
|
P
|
CHOP
|
R-CHOP
|
P
|
|---|
|
Total
|
135
|
376
| |
11
|
14
| |
|
Age
| | |
0.563
| | |
1.000
|
|
≤60 years
|
98 (72.6)
|
263 (69.9)
| |
8 (72.7)
|
10 (71.4)
| |
|
>60 years
|
37 (27.4)
|
113 (30.1)
| |
3 (27.3)
|
4 (28.6)
| |
|
Gender
| | |
0.694
| | |
0.115
|
|
Male
|
76 (56.3)
|
219 (58.2)
| |
5 (45.5)
|
11 (78.6)
| |
|
Female
|
59 (43.7)
|
157 (41.8)
| |
6 (54.5)
|
3 (21.4)
| |
|
Stage
| | |
0.892
| | |
0.434
|
|
I or II
|
77 (57.0)
|
217 (57.7)
| |
5 (45.5)
|
4 (28.6)
| |
|
III or IV
|
58 (43.0)
|
159 (42.3)
| |
6 (54.5)
|
10 (71.4)
| |
|
B symptoms
| | |
0.663
| | |
1.000
|
|
No
|
95 (70.4)
|
272 (72.3)
| |
7 (63.6)
|
8 (57.1)
| |
|
Yes
|
40 (29.6)
|
104 (27.7)
| |
4 (36.4)
|
6 (42.9)
| |
|
Bulky diseasea,b
| | |
0.238
| | |
0.500
|
|
No
|
91 (67.4)
|
252 (67.0)
| |
6 (54.5)
|
8 (57.1)
| |
|
Yes
|
10 (7.4)
|
17 (4.5)
| |
0 (0)
|
2 (14.3)
| |
|
Involved extranodal sitesc
| | |
0.617
| | |
0.414
|
|
≤1
|
112 (83.0)
|
303 (80.6)
| |
8 (72.7)
|
7 (50)
| |
|
>1
|
23 (17.0)
|
71 (18.9)
| |
3 (27.3)
|
7 (50)
| |
|
Sinus involvement
| | |
0.971
| | |
0.604
|
|
No
|
119 (88.1)
|
331 (88.0)
| |
10 (90.9)
|
11 (78.6)
| |
|
Yes
|
16 (11.9)
|
45 (12.0)
| |
1 (9.1)
|
3 (21.4)
| |
|
Bone involvement
| | |
0.947
| | |
0.407
|
|
No
|
120 (88.9)
|
335 (89.1)
| |
9 (81.8)
|
9 (64.3)
| |
|
Yes
|
15 (11.1)
|
41 (10.9)
| |
2 (18.2)
|
5 (35.7)
| |
|
Bone marrow involvement
| | |
0.177
| | |
0.230
|
|
No
|
133 (98.5)
|
360 (95.7)
| |
11 (100)
|
11 (78.6)
| |
|
Yes
|
2 (1.5)
|
16 (4.3)
| |
0 (0)
|
3 (21.4)
| |
|
Liver involvement
| | |
0.792
| | |
0.487
|
|
No
|
131 (97.0)
|
361 (96.0)
| |
11 (100)
|
12 (85.7)
| |
|
Yes
|
4 (3.0)
|
15 (4.0)
| |
0 (0)
|
2 (14.3)
| |
|
Testicular involvement
| | |
0.526
| | |
1.000
|
|
No
|
131 (97.0)
|
368 (97.9)
| |
11 (100)
|
13 (92.9)
| |
|
Yes
|
4 (3.0)
|
8 (2.1)
| |
0 (0)
|
1 (7.1)
| |
|
Renal involvement
| | |
0.782
| | |
0.661
|
|
No
|
130 (96.3)
|
360 (95.7)
| |
9 (81.8)
|
10 (71.4)
| |
|
Yes
|
5 (3.7)
|
16 (4.3)
| |
2 (18.2)
|
4 (28.6)
| |
|
Breast involvement
| | |
0.318
| | |
–
|
|
No
|
130 (96.3)
|
368 (97.9)
| |
11 (100)
|
14 (100)
| |
|
Yes
|
5 (3.7)
|
8 (2.1)
| |
0 (0)
|
0 (0)
| |
|
Female genital tract involvement
| | |
0.063
| | |
–
|
|
No
|
131 (97.0)
|
373 (99.2)
| |
11 (100)
|
14 (100)
| |
|
Yes
|
4 (3.0)
|
3 (0.8)
| |
0 (0)
|
0 (0)
| |
|
IPI
| | |
0.096
| | |
0.208
|
|
0–2
|
113 (83.7)
|
289 (76.9)
| |
9 (81.8)
|
7 (50.0)
| |
|
3–5
|
22 (16.3)
|
87 (23.1)
| |
2 (18.2)
|
7 (50.0)
| |
|
LDHd
| | |
0.768
| | |
0.677
|
|
≤1 ULNe
|
79 (58.5)
|
215 (57.2)
| |
3 (27.3)
|
6 (42.9)
| |
|
>1 ULN
|
55 (40.7)
|
159 (42.3)
| |
8 (72.7)
|
8 (57.1)
| |
|
ALB
| | |
0.464
| | |
0.656
|
|
<35 g/L
|
114 (84.4)
|
327 (87.0)
| |
4 (36.4)
|
3 (21.4)
| |
|
≥35 g/L
|
21 (15.6)
|
49 (13.0)
| |
7 (63.6)
|
11 (78.6)
| |
|
ALPf
| | |
0.529
| | |
1.000
|
|
≤110 U/L
|
119 (88.1)
|
341 (90.7)
| |
8 (72.7)
|
10 (71.4)
| |
|
>110 U/L
|
15 (11.1)
|
35 (9.3)
| |
3 (27.3)
|
4 (28.6)
| |
|
IT chemotherapy prophylaxisg
| | |
0.640
| | |
0.661
|
|
No
|
117 (86.7)
|
329 (87.5)
| |
9 (81.8)
|
10 (71.4)
| |
|
Yes
|
18 (13.3)
|
44 (11.7)
| |
2 (18.2)
|
4 (28.6)
| |
|
TTCh
| | |
0.016
| | |
0.003
|
|
≤108 days
|
54 (40.0)
|
207 (55.1)
| |
0 (0)
|
7 (50.0)
| |
|
>108 days
|
67 (49.6)
|
155 (41.2)
| |
10 (90.9)
|
3 (21.4)
| |
-
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, IPI international prognostic index, LDH lactate dehydrogenase, ULN upper limit of normal, ALB albumin, ALP alkaline phosphatase, IT intrathecal, TTC time to complete remission
-
aBulky disease: mass ≥7.5 cm
-
bIn the entire cohort, the data of 34 patients in the CHOP group and seven patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of five patients in the CHOP group and four patients in the R-CHOP group were missing
-
cIn the entire cohort, the data of two patients in the R-CHOP group were missing
-
dIn the entire cohort, the data of one patient in the CHOP group and two patients in the R-CHOP group were missing
-
fIn the entire cohort, the data of one patient in the CHOP group were missing
-
gIn the entire cohort, the data of three patients in the R-CHOP group were missing
-
hIn the entire cohort, the data of 14 patients in the CHOP group and 14 patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of one patient in the CHOP group and four patients in the R-CHOP group were missing
